Allison Tyler

558 total citations
23 papers, 393 citations indexed

About

Allison Tyler is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Allison Tyler has authored 23 papers receiving a total of 393 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Pulmonary and Respiratory Medicine, 11 papers in Oncology and 6 papers in Cancer Research. Recurrent topics in Allison Tyler's work include Prostate Cancer Treatment and Research (12 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Radiopharmaceutical Chemistry and Applications (4 papers). Allison Tyler is often cited by papers focused on Prostate Cancer Treatment and Research (12 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Radiopharmaceutical Chemistry and Applications (4 papers). Allison Tyler collaborates with scholars based in United States, United Kingdom and India. Allison Tyler's co-authors include Brian I. Rini, Jorge A. García, Diane Healey, Joe Stephenson, Mark N. Stein, Bo Huang, Simantini Eddy, Michael S. Gordon, Matthew M. Cooney and Pedro C. Barata and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and Cancer.

In The Last Decade

Allison Tyler

22 papers receiving 385 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Allison Tyler United States	10	220	194	149	108	52	23	393
M.E. Gleave Canada	8	183 0.8×	137 0.7×	172 1.2×	117 1.1×	51 1.0×	22	413
Guzmán Alonso Spain	8	161 0.7×	177 0.9×	66 0.4×	75 0.7×	43 0.8×	34	313
Chenfei Chi China	14	287 1.3×	177 0.9×	168 1.1×	168 1.6×	18 0.3×	26	489
Daniele Pozzessere Italy	14	175 0.8×	230 1.2×	114 0.8×	60 0.6×	103 2.0×	24	426
L. Hart United States	11	183 0.8×	254 1.3×	220 1.5×	66 0.6×	13 0.3×	25	518
V. Papadimitrakopoulou United States	13	304 1.4×	313 1.6×	223 1.5×	110 1.0×	29 0.6×	41	606
Minghan Jia China	10	102 0.5×	206 1.1×	133 0.9×	127 1.2×	28 0.5×	21	394
Marco Brugia Italy	12	128 0.6×	218 1.1×	117 0.8×	100 0.9×	26 0.5×	31	354
Teruhide Ishigame Japan	12	101 0.5×	141 0.7×	197 1.3×	132 1.2×	66 1.3×	36	406
Xin‐Gan Qin China	11	114 0.5×	96 0.5×	139 0.9×	69 0.6×	19 0.4×	25	316

Countries citing papers authored by Allison Tyler

Since Specialization

Citations

This map shows the geographic impact of Allison Tyler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Allison Tyler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Allison Tyler more than expected).

Fields of papers citing papers by Allison Tyler

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Allison Tyler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Allison Tyler. The network helps show where Allison Tyler may publish in the future.

Co-authorship network of co-authors of Allison Tyler

This figure shows the co-authorship network connecting the top 25 collaborators of Allison Tyler. A scholar is included among the top collaborators of Allison Tyler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Allison Tyler. Allison Tyler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Panettieri, Reynold A., Jason Roy, Allison Tyler, et al.. (2025). Leveraging Machine Learning and Real-World Data to Predict Chronic Obstructive Pulmonary Disease Exacerbations. International Journal of COPD. Volume 20. 3451–3459.

Tyler, Allison, et al.. (2023). LEVERAGING ARTIFICIAL INTELLIGENCE TO CREATE A CHRONIC OBSTRUCTIVE PULMONARY DISEASE EXACERBATION RISK ALGORITHM. CHEST Journal. 164(4). A4959–A4960. 1 indexed citations

Barata, Pedro C., Matthew M. Cooney, Prateek Mendiratta, et al.. (2018). Ketoconazole plus Lenalidomide in patients with Castration-Resistant Prostate Cancer (CRPC): results of an open-label phase II study. Investigational New Drugs. 36(6). 1085–1092. 6 indexed citations

Barata, Pedro C., Matthew M. Cooney, Allison Tyler, et al.. (2018). A phase 2 study of OSI-906 (linsitinib, an insulin-like growth factor receptor-1 inhibitor) in patients with asymptomatic or mildly symptomatic (non-opioid requiring) metastatic castrate resistant prostate cancer (CRPC). Investigational New Drugs. 36(3). 451–457. 33 indexed citations

Alyamani, Mohammad, Hamid Emamekhoo, Sunho Park, et al.. (2018). HSD3B1(1245A>C) variant regulates dueling abiraterone metabolite effects in prostate cancer. Journal of Clinical Investigation. 128(8). 3333–3340. 42 indexed citations

Barata, Pedro C., Vadim S. Koshkin, Prateek Mendiratta, et al.. (2018). Atezolizumab in Metastatic Urothelial Carcinoma Outside Clinical Trials: Focus on Efficacy, Safety, and Response to Subsequent Therapies. Targeted Oncology. 13(3). 353–361. 10 indexed citations

Barata, Pedro C., Alfonso Gómez de Liaño, Prateek Mendiratta, et al.. (2018). Clinical outcome of patients (Pts) with metastatic renal cell carcinoma (mRCC) progressing on front-line immune-oncology based combination (IO-COMBO) regimens.. Journal of Clinical Oncology. 36(6_suppl). 613–613. 6 indexed citations

Emamekhoo, Hamid, Pedro C. Barata, Cristina Magi‐Galluzzi, et al.. (2018). The association between HSD3B1 genotype and steroid metabolism in normal and prostate cancer (PCa) tissue.. Journal of Clinical Oncology. 36(6_suppl). TPS155–TPS155. 1 indexed citations

Ornstein, Moshe Chaim, Andrew J. Stephenson, Paul Elson, et al.. (2018). Adjuvant enzalutamide (Enza) for men with non-metastatic high-risk prostate cancer (HRPCa) after radical prostatectomy (RP).. Journal of Clinical Oncology. 36(6_suppl). 88–88. 3 indexed citations

10.

Barata, Pedro C., Hamid Emamekhoo, Prateek Mendiratta, et al.. (2018). Treatment patterns for metastatic hormone-sensitive prostate cancer (mHSPC) progressing after up-front docetaxel in combination with androgen deprivation therapy (D-ADT).. Journal of Clinical Oncology. 36(6_suppl). 305–305. 1 indexed citations

11.

Emamekhoo, Hamid, Mohammad Alyamani, Sunho Park, et al.. (2018). HSD3B1 genotype and abiraterone (Abi) metabolites in patients (pts) with prostate cancer (PCa).. Journal of Clinical Oncology. 36(6_suppl). 325–325. 1 indexed citations

12.

García, Jorge A., Robert Dreicer, Allan J. Pantuck, et al.. (2017). Clinical activity and safety of ASN001, a selective CYP17 lyase inhibitor, administered without prednisone in men with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 35(6_suppl). 240–240. 1 indexed citations

13.

Ornstein, Moshe Chaim, Andrew J. Stephenson, Paul Elson, et al.. (2016). Adjuvant enzalutamide (Enza) for men with high-risk prostate cancer (HRPCa) after radical prostatectomy (RP).. Journal of Clinical Oncology. 34(15_suppl). 5071–5071. 1 indexed citations

14.

Kuppachi, Sarat, Danniele G. Holanda, Michael Eberlein, et al.. (2016). An Unexpected Surge in Plasma BKPyV Viral Load Heralds the Development of BKPyV-Associated Metastatic Bladder Cancer in a Lung Transplant Recipient With BKPyV Nephropathy. American Journal of Transplantation. 17(3). 813–818. 14 indexed citations

15.

García, Jorge A., Paul Elson, Allison Tyler, Pierre L. Triozzi, & Robert Dreicer. (2013). Sargramostim (GM-CSF) and lenalidomide in castration-resistant prostate cancer (CRPC): Results from a phase I-II clinical trial. Urologic Oncology Seminars and Original Investigations. 32(1). 33.e11–33.e17. 15 indexed citations

16.

García, Jorge A., Paul Elson, Matthew M. Cooney, et al.. (2013). A phase II study of linsitinib (OSI-906) in patients with asymptomatic or mildly symptomatic (non-opioid requiring) metastatic castrate resistant prostate cancer (CRPC).. Journal of Clinical Oncology. 31(6_suppl). 197–197. 3 indexed citations

17.

Tyler, Allison. (2012). Urothelial Cancers: Ureter, Renal Pelvis, and Bladder. Seminars in Oncology Nursing. 28(3). 154–162. 10 indexed citations

18.

Murphy, Molly D., et al.. (2012). Assessment of owner willingness to treat or manage diseases of dogs and cats as a guide to shelter animal adoptability. Journal of the American Veterinary Medical Association. 242(1). 46–53. 10 indexed citations

19.

Rini, Brian I., Mark N. Stein, Simantini Eddy, et al.. (2010). Phase 1 dose‐escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma. Cancer. 117(4). 758–767. 119 indexed citations

20.

Rini, Brian I., Jorge A. García, Matthew M. Cooney, et al.. (2009). A Phase I Study of Sunitinib plus Bevacizumab in Advanced Solid Tumors. Clinical Cancer Research. 15(19). 6277–6283. 65 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact